# üß¨ PATHWAY VALIDATION DATA REQUIREMENTS

**Version**: 1.0  
**Date**: November 28, 2024  
**Owner**: Manager Agent  
**Purpose**: Define ALL data needed to validate ALL 7 pathways across ALL relevant cancer types

---

## üéØ MISSION

Validate mechanism-based predictions for:
1. **Trial matching** - Match patient pathways to trial drug mechanisms
2. **Resistance prediction** - Predict who will develop treatment resistance
3. **Sensitivity prediction** - Predict who will respond to specific therapies

**Core Focus**: Ovarian cancer and its closest ancestors (gynecological cancers)  
**Extended Scope**: All major solid tumors where our 7 pathways are clinically relevant

---

## üìä THE 7 PATHWAYS WE MUST VALIDATE

| Index | Pathway | Key Genes | Clinical Relevance |
|-------|---------|-----------|-------------------|
| 0 | **DDR** | BRCA1, BRCA2, ATM, ATR, PALB2, RAD51, CHEK2 | PARP inhibitors, platinum sensitivity |
| 1 | **MAPK** | BRAF, KRAS, NRAS, NF1, MEK1/2 | BRAF/MEK inhibitors, resistance |
| 2 | **PI3K** | PIK3CA, PTEN, AKT1, MTOR | PI3K inhibitors (alpelisib) |
| 3 | **VEGF** | VEGFA, VHL, HIF1A, KDR | Anti-angiogenics (bevacizumab) |
| 4 | **HER2** | ERBB2/HER2, ERBB3 | Trastuzumab, T-DXd |
| 5 | **IO** | CD274/PD-L1, TMB, MSI, POLE | Checkpoint inhibitors |
| 6 | **Efflux** | ABCB1/MDR1, ABCC1, ABCG2 | Multi-drug resistance |

---

## üî¨ CANCER TYPE PRIORITIES

### TIER 1: CORE FOCUS (Gynecological)

| Cancer | TCGA Code | Priority | Why |
|--------|-----------|----------|-----|
| **Ovarian (HGSOC)** | TCGA-OV | P0 | Primary focus, have 469 patients |
| **Endometrial** | TCGA-UCEC | P1 | Sister cancer, high PI3K/MSI |
| **Cervical** | TCGA-CESC | P1 | Sister cancer, HPV-related |

### TIER 2: PATHWAY VALIDATION (High Signal)

| Cancer | TCGA Code | Priority | Primary Pathway |
|--------|-----------|----------|-----------------|
| **Breast** | TCGA-BRCA | P2 | DDR (BRCA), HER2, PI3K |
| **Melanoma** | TCGA-SKCM | P2 | MAPK (BRAF), IO |
| **Lung Adeno** | TCGA-LUAD | P2 | MAPK (KRAS), IO |
| **Colorectal** | TCGA-COAD | P2 | MAPK (KRAS/BRAF) |

### TIER 3: COMPLETE COVERAGE

| Cancer | TCGA Code | Priority | Primary Pathway |
|--------|-----------|----------|-----------------|
| **Kidney Clear Cell** | TCGA-KIRC | P3 | VEGF (VHL) |
| **Pancreatic** | TCGA-PAAD | P3 | DDR, MAPK (KRAS) |
| **Prostate** | TCGA-PRAD | P3 | DDR (BRCA2) |
| **Gastric** | TCGA-STAD | P3 | HER2, MSI |
| **Bladder** | TCGA-BLCA | P3 | IO (TMB) |

---

## üìÅ DATA REQUIREMENTS PER CANCER TYPE

### For EACH cancer type, we need:

```yaml
cancer_type:
  tcga_code: "TCGA-XX"
  
  # REQUIRED: Mutation Data
  mutations:
    source: "cBioPortal or TCGA GDC"
    format: "MAF or JSON"
    fields:
      - patient_id
      - gene
      - hgvs_p (protein change)
      - hgvs_c (cDNA change)
      - variant_classification
      - chromosome
      - position
      - ref_allele
      - alt_allele
    min_patients: 100
    
  # REQUIRED: Treatment Response Data
  treatment_response:
    source: "TCGA clinical, cBioPortal, or trial data"
    format: "JSON or TSV"
    fields:
      - patient_id
      - treatment_type (chemo, targeted, IO)
      - drug_name
      - response (CR, PR, SD, PD)
      - response_category (sensitive, resistant, refractory)
      - pfs_months (if available)
      - os_months (if available)
    min_patients_with_response: 50
    
  # OPTIONAL: Biomarker Data
  biomarkers:
    fields:
      - hrd_score
      - tmb_score
      - msi_status
      - pd_l1_expression
    source: "TCGA or computed from mutations"
    
  # OPTIONAL: Copy Number Data
  copy_number:
    fields:
      - gene
      - cn_status (amplification, deletion, neutral)
      - log2_ratio
    source: "TCGA GISTIC or cBioPortal"
```

---

## üìã SPECIFIC DATA REQUESTS BY CANCER TYPE

### 1. OVARIAN CANCER (TCGA-OV) - ‚úÖ HAVE PARTIAL

**Current Status**: 469 patients with mutations + platinum response

**What We Have**:
- ‚úÖ Mutations for 469 patients
- ‚úÖ Platinum response (sensitive/resistant/refractory)
- ‚ùå Missing: HRD scores
- ‚ùå Missing: PARP inhibitor response
- ‚ùå Missing: Bevacizumab response

**Additional Data Needed**:
```yaml
ovarian_additional:
  hrd_scores:
    source: "TCGA HRD paper or Myriad-style computation"
    patients_needed: 469 (match existing)
    fields: [genomic_loh_score, tai_score, lst_score, hrd_sum]
    
  parp_response:
    source: "ARIEL trials, PRIMA trial, or real-world data"
    fields: [patient_id, parp_drug, response, pfs_months]
    min_patients: 50
    
  io_response:
    source: "KEYNOTE trials, IMagyn050"
    fields: [patient_id, io_drug, response, pfs_months]
    min_patients: 30
```

### 2. ENDOMETRIAL CANCER (TCGA-UCEC) - ‚è∏Ô∏è NEED

**Why Important**: 
- High PI3K mutation rate (40% PIK3CA)
- High MSI rate (30%) - IO validation
- Sister cancer to ovarian

**Data Needed**:
```yaml
endometrial:
  mutations:
    source: "cBioPortal TCGA-UCEC"
    expected_patients: 500+
    key_genes: [PIK3CA, PTEN, KRAS, TP53, ARID1A, POLE]
    
  msi_status:
    source: "TCGA molecular subtypes"
    categories: [MSI-H, MSS, POLE-ultramutated]
    
  treatment_response:
    source: "TCGA clinical or PORTEC trials"
    treatments: [platinum, taxane, checkpoint_inhibitor]
    
  validation_targets:
    - PI3K pathway vs response
    - MSI-H vs IO response
    - POLE vs IO response
```

### 3. CERVICAL CANCER (TCGA-CESC) - ‚è∏Ô∏è NEED

**Why Important**:
- HPV-related (different biology)
- IO increasingly used
- Sister cancer to ovarian

**Data Needed**:
```yaml
cervical:
  mutations:
    source: "cBioPortal TCGA-CESC"
    expected_patients: 300+
    key_genes: [PIK3CA, PTEN, KRAS, STK11, FBXW7]
    
  hpv_status:
    source: "TCGA"
    categories: [HPV+, HPV-]
    
  treatment_response:
    source: "GOG trials, KEYNOTE-826"
    treatments: [platinum, paclitaxel, pembrolizumab, bevacizumab]
```

### 4. BREAST CANCER (TCGA-BRCA) - ‚è∏Ô∏è NEED

**Why Important**:
- Highest BRCA1/2 frequency (validate DDR)
- HER2+ subset (validate HER2)
- PIK3CA common (validate PI3K)

**Data Needed**:
```yaml
breast:
  mutations:
    source: "cBioPortal TCGA-BRCA"
    expected_patients: 1000+
    key_genes: [BRCA1, BRCA2, PIK3CA, ERBB2, TP53, CDH1]
    
  subtypes:
    source: "TCGA PAM50"
    categories: [Luminal_A, Luminal_B, HER2_enriched, Basal, Normal]
    
  her2_status:
    source: "TCGA clinical"
    categories: [HER2+, HER2-]
    
  treatment_response:
    source: "I-SPY, CALGB, or cBioPortal clinical"
    treatments:
      - neoadjuvant_chemo (pCR yes/no)
      - trastuzumab (HER2+ response)
      - parp_inhibitor (BRCA+ response)
      - alpelisib (PIK3CA+ response)
      
  validation_targets:
    - BRCA1/2 vs platinum/PARP response
    - HER2 amp vs trastuzumab response
    - PIK3CA vs alpelisib response
```

### 5. MELANOMA (TCGA-SKCM) - ‚è∏Ô∏è NEED

**Why Important**:
- BRAF V600E 50% (validate MAPK)
- IO standard of care (validate IO)
- High TMB (validate IO)

**Data Needed**:
```yaml
melanoma:
  mutations:
    source: "cBioPortal TCGA-SKCM"
    expected_patients: 400+
    key_genes: [BRAF, NRAS, NF1, KIT, CDKN2A]
    
  braf_status:
    source: "TCGA or derived from mutations"
    categories: [V600E, V600K, other_BRAF, BRAF_WT]
    
  tmb_score:
    source: "Computed from mutations"
    threshold: 10 mut/Mb for TMB-high
    
  treatment_response:
    source: "CheckMate, KEYNOTE, coBRIM trials"
    treatments:
      - braf_inhibitor (vemurafenib, dabrafenib)
      - mek_inhibitor (trametinib, cobimetinib)
      - anti_pd1 (nivolumab, pembrolizumab)
      - anti_ctla4 (ipilimumab)
      
  validation_targets:
    - BRAF V600 vs BRAF inhibitor response
    - TMB-high vs IO response
    - NF1 vs MAPK inhibitor resistance
```

### 6. LUNG ADENOCARCINOMA (TCGA-LUAD) - ‚è∏Ô∏è NEED

**Why Important**:
- KRAS mutations common (30%)
- IO standard of care
- EGFR mutations (Asian populations)

**Data Needed**:
```yaml
lung_adeno:
  mutations:
    source: "cBioPortal TCGA-LUAD"
    expected_patients: 500+
    key_genes: [KRAS, EGFR, ALK, ROS1, BRAF, STK11, KEAP1]
    
  pd_l1_expression:
    source: "TCGA or trial data"
    categories: [high_‚â•50%, low_1-49%, negative_<1%]
    
  tmb_score:
    source: "Computed from mutations"
    
  treatment_response:
    source: "KEYNOTE-024, CheckMate-227"
    treatments:
      - platinum_doublet
      - anti_pd1 (pembrolizumab, nivolumab)
      - egfr_tki (for EGFR+)
      - kras_g12c (sotorasib for KRAS G12C)
      
  validation_targets:
    - KRAS vs KRAS inhibitor response
    - TMB-high vs IO response
    - STK11 vs IO resistance
```

### 7. COLORECTAL CANCER (TCGA-COAD) - ‚è∏Ô∏è NEED

**Why Important**:
- KRAS/BRAF common (validate MAPK)
- MSI-H subset (validate IO)
- Anti-EGFR therapy stratification

**Data Needed**:
```yaml
colorectal:
  mutations:
    source: "cBioPortal TCGA-COAD + TCGA-READ"
    expected_patients: 600+
    key_genes: [KRAS, NRAS, BRAF, PIK3CA, APC, TP53]
    
  msi_status:
    source: "TCGA molecular subtypes"
    categories: [MSI-H, MSS]
    
  treatment_response:
    source: "CALGB, KEYNOTE-177"
    treatments:
      - folfox
      - folfiri
      - anti_egfr (cetuximab - only RAS WT)
      - anti_vegf (bevacizumab)
      - anti_pd1 (MSI-H only)
      
  validation_targets:
    - KRAS/NRAS vs anti-EGFR resistance
    - BRAF V600E vs poor prognosis
    - MSI-H vs IO response
```

### 8. KIDNEY CLEAR CELL (TCGA-KIRC) - ‚è∏Ô∏è NEED

**Why Important**:
- VHL mutations 80% (validate VEGF)
- Anti-VEGF standard of care
- IO combinations

**Data Needed**:
```yaml
kidney:
  mutations:
    source: "cBioPortal TCGA-KIRC"
    expected_patients: 500+
    key_genes: [VHL, PBRM1, SETD2, BAP1, KDM5C]
    
  treatment_response:
    source: "CheckMate-214, KEYNOTE-426"
    treatments:
      - sunitinib
      - pazopanib
      - cabozantinib
      - nivolumab_ipilimumab
      - pembrolizumab_axitinib
      
  validation_targets:
    - VHL mutation vs TKI response
    - BAP1 vs poor prognosis
    - PBRM1 vs IO response
```

---

## üì• DATA SOURCES

### Primary Sources (Free, Public)

| Source | URL | Data Type |
|--------|-----|-----------|
| **cBioPortal** | https://www.cbioportal.org/ | Mutations, clinical, CNA |
| **GDC Data Portal** | https://portal.gdc.cancer.gov/ | TCGA raw data |
| **ICGC** | https://dcc.icgc.org/ | International cancer genomes |
| **EGA** | https://ega-archive.org/ | European trial data |

### cBioPortal API for Programmatic Access

```python
# Example: Download TCGA-BRCA mutations
import requests

base_url = "https://www.cbioportal.org/api"
study_id = "brca_tcga_pan_can_atlas_2018"

# Get mutations
mutations_url = f"{base_url}/studies/{study_id}/mutations"
response = requests.get(mutations_url)
mutations = response.json()
```

### Trial Data Sources

| Trial | Cancer | Pathway | Data Availability |
|-------|--------|---------|-------------------|
| ARIEL2/3 | Ovarian | DDR | Request from Clovis |
| PRIMA | Ovarian | DDR | Request from GSK |
| SOLAR-1 | Breast | PI3K | cBioPortal |
| BOLERO-2 | Breast | PI3K | cBioPortal |
| CheckMate-067 | Melanoma | IO | Request from BMS |
| KEYNOTE-006 | Melanoma | IO | Request from Merck |

---

## üéØ VALIDATION MATRIX

### What We Need to Prove for Each Pathway

| Pathway | Validation Goal | Metric | Target |
|---------|-----------------|--------|--------|
| **DDR** | BRCA ‚Üí platinum/PARP response | Sensitivity rate difference | >10% |
| **MAPK** | BRAF ‚Üí BRAF-i response | ORR difference | >30% |
| **MAPK** | NF1 ‚Üí resistance | Resistance enrichment | >2x |
| **PI3K** | PIK3CA ‚Üí alpelisib response | PFS difference | >2 months |
| **VEGF** | VHL ‚Üí TKI response | Response rate | >50% |
| **HER2** | HER2+ ‚Üí trastuzumab response | pCR rate | >40% |
| **IO** | TMB-high ‚Üí IO response | ORR difference | >20% |
| **IO** | MSI-H ‚Üí IO response | ORR | >40% |
| **Efflux** | MDR1 high ‚Üí resistance | Resistance rate | >2x baseline |

---

## üìä MINIMUM VIABLE DATASET

### To claim pathway validation, we need:

```yaml
minimum_requirements:
  patients_per_group: 30  # Min 30 in each arm
  
  for_sensitivity_validation:
    - mutation_positive: 30+ patients
    - mutation_negative: 30+ patients
    - treatment_response: binary (responder/non-responder)
    
  for_resistance_validation:
    - resistant_patients: 30+ patients
    - sensitive_patients: 30+ patients
    - mutation_data: complete
    
  statistical_threshold:
    - p_value: <0.05
    - relative_risk: >1.5 or <0.67
    - confidence_interval: 95%
```

---

## üöÄ AGENT INSTRUCTIONS

### For Data Acquisition Agents:

1. **Start with cBioPortal** - Easiest programmatic access
2. **Download mutation + clinical data together** - They must be linkable by patient_id
3. **Prioritize treatment response data** - This is the hardest to find
4. **Document data provenance** - Source, date, version
5. **Save in standardized JSON format** - See schema below

### Standard Output Format:

```json
{
  "cancer_type": "TCGA-BRCA",
  "source": "cBioPortal",
  "download_date": "2024-11-28",
  "patients": [
    {
      "patient_id": "TCGA-XX-XXXX",
      "mutations": [
        {
          "gene": "BRCA1",
          "hgvs_p": "p.E1685*",
          "variant_classification": "Nonsense_Mutation"
        }
      ],
      "treatment_response": {
        "treatment": "platinum",
        "response": "sensitive",
        "pfs_months": 18.5
      },
      "biomarkers": {
        "hrd_score": 42,
        "tmb": 3.2,
        "msi_status": "MSS"
      }
    }
  ],
  "summary": {
    "total_patients": 1084,
    "patients_with_response": 523,
    "pathway_mutations": {
      "BRCA1": 45,
      "BRCA2": 32,
      "PIK3CA": 341
    }
  }
}
```

---

## ‚úÖ SUCCESS CRITERIA

### Phase 1: Gynecological Cancers (2 weeks)
- [ ] Ovarian: DDR, MAPK, VEGF validated
- [ ] Endometrial: PI3K, IO validated  
- [ ] Cervical: IO validated

### Phase 2: High-Signal Cancers (2 weeks)
- [ ] Breast: DDR, HER2, PI3K validated
- [ ] Melanoma: MAPK, IO validated
- [ ] Lung: MAPK, IO validated

### Phase 3: Complete Coverage (2 weeks)
- [ ] All 7 pathways validated in at least 2 cancer types each
- [ ] Cross-cancer validation (same pathway, different cancers)
- [ ] Resistance prediction validated in 3+ cancers

### Final Deliverable
- Validation matrix: 7 pathways √ó 10+ cancer types
- Real metrics (not synthetic): Relative risk, sensitivity lift, AUC
- Production-ready pathway weights per cancer type

---

## üìû SUPPORT NEEDED

### From Data Agents:
1. Download cBioPortal datasets for each cancer type
2. Extract treatment response where available
3. Compute derived biomarkers (HRD, TMB)
4. Link mutations to outcomes

### From Validation Agents:
1. Run statistical tests per pathway √ó cancer
2. Calculate relative risk, sensitivity/specificity
3. Identify which pathways work in which cancers
4. Build cancer-specific pathway weights

### From Manager:
1. Coordinate data acquisition
2. Review validation results
3. Update this document with findings
4. Report honest metrics only

---

**End of Data Requirements Document**

**Status**: ACTIVE - Awaiting agent execution  
**Next Step**: Agents begin data acquisition from cBioPortal
